FindTrial
Sign In

Utility Of Brain EEG and its changes In Detecting and Monitoring Before and After LACTULOSE THERAPY In Chronic Liver Disease Patients With Altered Sensorium

BISPECTRAL INDEX MONITORING BEFORE AND AFTER LACTULOSE THERAPY IN CIRRHOTIC PATIENTS WITH OVERT AND MINIMAL HEPATIC ENCEPHALOPATHY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/03/004493
Enrollment
160
Registered
2014-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cirrhotic Patients

Interventions

Intervention1: Lactulose: Dose is 10-15 ml orally twice or thrice daily till patient passes 2-3 soft stools. duration varying from 1 week upto 3 months Control Intervention1: BIS INDEX Monitor: ASPECT

Sponsors

Deptt of Gastroenterology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cirrhotic Patients

Exclusion criteria

Exclusion criteria: Use of sedatives, hypnotics or psychotropic drugs Concomitant neurological disorders affecting the mental state such as stroke, stupor, or dementia Patients on lactulose therapy in last 6 weeks

Design outcomes

Primary

MeasureTime frame
Grade of Hepatic EncephalopathyTimepoint: One week in Case of Overt Hepatic Encephalopathy, Three months in Case of minimal Hepatic Encephalopathy—

Secondary

MeasureTime frame
Recovery from Hepatic Encephalopathy /DeathTimepoint: 3 months—

Countries

India

Contacts

Public ContactAmit Jindal

G B Pant Hospital,New Delhi

drbcsharma@hotmail.com09718599212

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026